Advanced search×

Glycated hemoglobin predicts all-cause, cardiovascular, and cancer mortality in people without a history of diabetes undergoing coronary angiography.

Guenther G Silbernagel, Tanja B TB Grammer, Bernhard R BR Winkelmann, Bernhard O BO Boehm, and Winfried W März

Diabetes Care 34(6):1355-61 (2011) PMID 21515847 PMCID PMC3114349

Glycated hemoglobin has been suggested to be superior to fasting glucose for the prediction of vascular disease and death from any cause. The aim of the present work was to analyze and compare the predictive value of glycated hemoglobin and fasting glucose on all-cause and cause-specific mortality in subjects who underwent coronary angiography.

DOI: 10.2337/dc10-2010
Version: za2963e q8za0 q8zbd q8zc3 q8zd4 q8zed q8zfd q8zg8
View PDF

Similar articles you may find interesting…

  1. Determinants of Progression of Aortic Stiffness in Hemodialysis Patients: A Prospective Longitudinal Study.
    Mihai S Utescu, Véronique Couture, and Mohsen Agharazii

    Hypertension (2013) PMID 23648699

    We examined the impact of age, atherosclerotic cardiovascular disease, diabetes mellitus, dialysis vintage, and pentosidine (a well-characterized, advanced glycation end products) on the rate of progression of aortic stiffness. The annual rate of changes in carotid-femoral pulse wave velocity and ca...
    Buy PDF
  2. n-3 fatty acids in patients with multiple cardiovascular risk factors.
    Risk and Prevention Study Collaborative Group, Maria Carla Roncaglioni, and Roberto Marchioli

    N Engl J Med 368(19):1800-8 (2013) PMID 23656645

    We evaluated the potential benefit of such therapy in patients with multiple cardiovascular risk factors or atherosclerotic vascular disease who had not had a myocardial infarction. In this double-blind, placebo-controlled clinical trial, we enrolled a cohort of patients who were fol...
    Buy PDF
  3. Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour disseminatio...
    M Vives, M M Ginestà, and F Viñals

    Int J Cancer (2013) PMID 23649709

    We report the effectiveness of a multi-targeted chemo-switch schedule (C-S) that combines metronomic chemotherapy (MET) after treatment with the maximum tolerated dose (MTD). We tested this schedule with gemcitabine in two distinct human pancreatic adenocarcinoma orthotopic models and with cyclophos...
    Buy PDF